CD4 and plasma cell myeloma: 5TMM has also been used to examine immunomodulatory myeloma treatments at the preclinical level; e.g., investigators demonstrated that CD4 T cells were vital for lenalidomide’s activity, while NK, B or CD8 T cells were not (103).